Advice

following an abbreviated submission:

romiplostim (Nplate) is accepted for restricted use within NHSScotland.

Indication under review: chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)

SMC restriction: to use in patients with severe symptomatic ITP or patients with a high risk of bleeding.

Romiplostim has previously been accepted for restricted use in adults with ITP. The licence has now been extended to use in children from the age of 1 year.

Download detailed advice358KB (PDF)

Download

Medicine details

Medicine name:
romiplostim (Nplate)
SMC ID:
SMC2126
Indication:
Chronic immune (idiopathic) thrombocytopenic purpura patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)
Pharmaceutical company
Amgen Ltd
BNF chapter
Nutrition and blood
Submission type
Abbreviated submission
Status
Restricted
Date advice published:
11 February 2019